99:@0.895357:0.033217:0.916054:0.033217:0.916054:0.013052:0.895357:0.013052:0.010348:0.010348
HANDBOOK OF GENERAL MEDICINE VOL 1:@0.649278:0.972666:0.923020:0.972666:0.923020:0.958637:0.649278:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
TREATMENT AppROACHEs:@0.983817:0.243404:0.983817:0.056390:0.958557:0.056390:0.958557:0.243404:0.008796:-0.015759:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.114251:0.006043:0.014598:-0.134892:0.158618:-0.158618:0.000000:0.000000:0.000000:0.000000:0.242660:0.009202
TREATMENT AppROACHEs:@0.397039:0.033156:0.624383:0.033156:0.624383:0.013866:0.397039:0.013866:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
10.  Klug E, Raal FJ, Marais AD, :@0.076190:0.082219:0.251803:0.082219:0.251803:0.069944:0.076190:0.069944:0.006515:0.006515:0.003257:0.003257:0.005656:0.006950:0.002352:0.007150:0.007914:0.002999:0.006303:0.003257:0.002999:0.007138:0.008032:0.008032:0.002352:0.003010:0.005703:0.005668:0.003257:0.002999:0.010807:0.008032:0.003540:0.008032:0.002352:0.004563:0.003010:0.008702:0.008749:0.003257:0.003257
et al.:@0.251544:0.082219:0.279814:0.082219:0.279814:0.069944:0.251544:0.069944:0.007644:0.003986:0.002999:0.008032:0.002352:0.003257
 south African dyslipidaemia guide-:@0.279814:0.082219:0.480967:0.082219:0.480967:0.069944:0.279814:0.069944:0.003010:0.005856:0.007702:0.007150:0.003986:0.007173:0.002999:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.007173:0.002999:0.008055:0.006303:0.004563:0.002352:0.002352:0.008020:0.002352:0.008055:0.008032:0.007644:0.011030:0.002352:0.008032:0.003022:0.007914:0.007150:0.002352:0.008055:0.007644:0.003904
line consensus statement:  2018  update. A joint statement  from :@0.101402:0.093121:0.484236:0.093121:0.484236:0.080845:0.101402:0.080845:0.002352:0.002352:0.007173:0.007644:0.006515:0.007608:0.007702:0.007173:0.004563:0.007644:0.007173:0.004563:0.007150:0.004563:0.006515:0.004563:0.003986:0.008032:0.003986:0.007644:0.011030:0.007644:0.007173:0.003986:0.003257:0.003257:0.003246:0.006515:0.006515:0.006515:0.006515:0.003257:0.003269:0.007150:0.008020:0.008055:0.008032:0.003986:0.007644:0.003257:0.006515:0.008702:0.006515:0.002387:0.007702:0.002352:0.007173:0.003986:0.006515:0.004563:0.003986:0.008032:0.003986:0.007644:0.011030:0.007644:0.007173:0.003986:0.003257:0.003246:0.003692:0.003540:0.007702:0.011030:0.003257
the south African Heart Association (sA Heart) and the Lipid and :@0.101402:0.104022:0.484213:0.104022:0.484213:0.091747:0.101402:0.091747:0.003986:0.007173:0.007644:0.004574:0.005856:0.007702:0.007150:0.003986:0.007173:0.004574:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.007173:0.004574:0.008032:0.007644:0.008032:0.003540:0.003986:0.004586:0.008702:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.004586:0.004339:0.005856:0.008702:0.004586:0.008032:0.007644:0.008032:0.003540:0.003986:0.004339:0.004586:0.008032:0.007173:0.008055:0.004586:0.003986:0.007173:0.007644:0.004574:0.005433:0.002352:0.008020:0.002352:0.008055:0.004586:0.008032:0.007173:0.008055:0.003257
Atherosclerosis  society of  southern  Africa (LAssA). :@0.101402:0.114924:0.402451:0.114924:0.402451:0.102648:0.101402:0.102648:0.008702:0.003986:0.007173:0.007644:0.003540:0.007702:0.004563:0.007608:0.002352:0.007644:0.003540:0.007702:0.004563:0.002352:0.004563:0.003257:0.002881:0.005856:0.007702:0.007608:0.002352:0.007644:0.003986:0.006303:0.006138:0.007702:0.003692:0.003257:0.002881:0.005856:0.007702:0.007150:0.003986:0.007173:0.007644:0.003540:0.007173:0.003257:0.002869:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.006138:0.004339:0.005433:0.008702:0.005856:0.005856:0.008702:0.004339:0.003257:0.003257
S Afr Med J.:@0.405332:0.114924:0.480967:0.114924:0.480967:0.102648:0.405332:0.102648:0.005856:0.006138:0.008702:0.003692:0.003540:0.006138:0.010807:0.007644:0.008055:0.006138:0.005668:0.003257
 :@0.480967:0.114924:0.484225:0.114924:0.484225:0.102648:0.480967:0.102648:0.003257
2018;108(11b):973-1000.:@0.101402:0.125825:0.236010:0.125825:0.236010:0.113550:0.101402:0.113550:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.008020:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
11.  Mc Causland  FR, Claggett B, Burdmann EA, :@0.076202:0.136727:0.378168:0.136727:0.378168:0.124451:0.076202:0.124451:0.006515:0.006515:0.003257:0.003257:0.005656:0.010807:0.007608:0.007585:0.009560:0.008032:0.007150:0.004563:0.002352:0.008032:0.007173:0.008055:0.003257:0.004339:0.005703:0.007138:0.003257:0.007585:0.009560:0.002352:0.008032:0.007914:0.007914:0.007644:0.003986:0.003986:0.007585:0.006750:0.003257:0.007585:0.006750:0.007150:0.003540:0.008055:0.011030:0.008032:0.007173:0.007173:0.007585:0.006303:0.008702:0.003257:0.003257
et al.:@0.382495:0.136727:0.415351:0.136727:0.415351:0.124451:0.382495:0.124451:0.007644:0.003986:0.007585:0.008032:0.002352:0.003257
 Treatment :@0.415351:0.136727:0.484236:0.136727:0.484236:0.124451:0.415351:0.124451:0.007585:0.005009:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.003257
of  anemia with  darbepoetin  before  dialysis  initiation and  clini-:@0.101402:0.147628:0.480956:0.147628:0.480956:0.135353:0.101402:0.135353:0.007702:0.003692:0.003257:0.003634:0.008032:0.007173:0.007644:0.011030:0.002352:0.008032:0.006903:0.009772:0.002352:0.003986:0.007173:0.003257:0.003634:0.008055:0.008032:0.003540:0.008020:0.007644:0.008020:0.007702:0.007644:0.003986:0.002352:0.007173:0.003257:0.003634:0.008020:0.007644:0.003692:0.007702:0.003540:0.007644:0.003257:0.003634:0.008055:0.002352:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.003257:0.003657:0.002352:0.007173:0.002352:0.003986:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.006903:0.008032:0.007173:0.008055:0.003257:0.003634:0.007608:0.002352:0.002352:0.007173:0.002352:0.003904
cal outcomes:  Analyses from the trial to reduce cardiovascular :@0.101402:0.158530:0.484213:0.158530:0.484213:0.146254:0.101402:0.146254:0.007608:0.008032:0.002352:0.006021:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003257:0.003257:0.002752:0.008702:0.007173:0.008032:0.002352:0.006303:0.004563:0.007644:0.004563:0.006021:0.003692:0.003540:0.007702:0.011030:0.006021:0.003986:0.007173:0.007644:0.006021:0.003986:0.003540:0.002352:0.008032:0.002352:0.006021:0.003986:0.007702:0.006021:0.003540:0.007644:0.008055:0.007150:0.007608:0.007644:0.006021:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003257
events with aranesp therapy (TREAT). :@0.101402:0.169431:0.316832:0.169431:0.316832:0.157156:0.101402:0.157156:0.007644:0.006515:0.007644:0.007173:0.003986:0.004563:0.003892:0.009772:0.002352:0.003986:0.007173:0.003892:0.008032:0.003540:0.008032:0.007173:0.007644:0.004563:0.008020:0.003892:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303:0.003892:0.004339:0.005009:0.007138:0.006303:0.008702:0.005009:0.004339:0.003257:0.003257
Am J Kidney Dis:@0.317455:0.169431:0.408671:0.169431:0.408671:0.157156:0.317455:0.157156:0.008702:0.011030:0.003892:0.005668:0.003892:0.006950:0.002352:0.008055:0.007173:0.007644:0.006303:0.003892:0.008749:0.002352:0.004563
. 2018;s0272-:@0.408671:0.169431:0.480956:0.169431:0.480956:0.157156:0.408671:0.157156:0.003257:0.003892:0.006515:0.006515:0.006515:0.006515:0.003257:0.005856:0.006515:0.006515:0.006515:0.006515:0.003904
6386(18):31087-4.:@0.101402:0.180333:0.198675:0.180333:0.198675:0.168057:0.101402:0.168057:0.006515:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.003257